<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730652</url>
  </required_header>
  <id_info>
    <org_study_id>MDX1411-02</org_study_id>
    <nct_id>NCT00730652</nct_id>
  </id_info>
  <brief_title>Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma</brief_title>
  <acronym>MDX1411-02</acronym>
  <official_title>A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1411 Administered Every 7 Days in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if MDX-1411 is safe for the treatment of chronic lymphocytic leukemia or mantle
      cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose-escalation, multidose study of MDX-1411, a fully human nonfucosylated monoclonal
      antibody (mAb) targeting the CD70 transmembrane cell-surface protein, which is highly
      expressed in B-cell malignancies such as CLL and MCL.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor Decision
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Profile of MDX-1411 and determine the maximum tolerated dose (MTD)</measure>
    <time_frame>Day 1-40</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.</condition>
  <arm_group>
    <arm_group_label>MDX1411</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An accelerated titration design (ATD) will be utilized and subjects will be assigned to a dose level in the order they enter the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MDX-1411</intervention_name>
    <description>Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.</description>
    <arm_group_label>MDX1411</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of relapsed/refractory MCL or hematologically/bone
             marrow confirmed relapsed/refractory CLL that is not amenable to cure by surgery or
             other means and has failed at least 1 prior systemic therapy;

          -  Subjects may have been treated with up to 6 prior systemic therapies for
             relapsed/refractory disease or have become intolerant to a systemic therapy

          -  For MCL, must have measurable disease

          -  At least 4 weeks since the last systemic therapy, including RT, for the treatment of
             MCL/CLL;

          -  At least 4 weeks since taking any corticosteroids prior to the first dose of MDX-1411

          -  ECOG Performance Status 0 to 2;

          -  No known positivity for human immunodeficiency virus (HIV) and no active infection
             with Hepatitis B or Hepatitis C;

        Exclusion Criteria:

          -  History of severe hypersensitivity reactions to other monoclonal antibodies;

          -  Use of other investigational drugs within 30 days before study drug administration

          -  Prior treatment with any other anti-CD70 antibody;

          -  Active infection requiring i.v. systemic therapy within 4 weeks of receiving the first
             dose of MDX-1411;

          -  Evidence of bleeding diathesis or coagulopathy;

          -  Active autoimmune disease requiring immunosuppressive therapy;

          -  Known current drug or alcohol abuse;

          -  Underlying medical conditions that will make the administration of MDX-1411 hazardous
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medarex Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Medarex</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>April 21, 2010</last_update_submitted>
  <last_update_submitted_qc>April 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <keyword>Medarex Inc.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

